Bio-Rad Laboratories Analyst Price Targets

Wall Street analyst price targets and consensus rating for Bio-Rad Laboratories (BIO).

Price Target Range — 12 Quarters

Analyst Consensus — 4 Analysts

2Buy

2Hold

Consensus RatingEqual-Weight# Analysts4Avg. Consensus PT$334Upside to Avg. PT-14.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 7, 2026	RBC Capital	Dan Leonard	PT Raise	Outperform	$370→$390
Aug 5, 2026	Citigroup	Daniel Grosslight	PT Raise	Neutral	$300→$330
Aug 5, 2026	RBC Capital	Dan Leonard	PT Raise	Outperform	$320→$370
Aug 5, 2026	Wells Fargo	Evan Stampler	PT Raise	Equal-Weight	$310→$330
May 15, 2026	RBC Capital	Dan Leonard	Reinstates	Outperform	$320
May 1, 2026	Wells Fargo	Brandon Couillard	PT Cut	Equal-Weight	$320→$290
Apr 7, 2026	Citigroup	Patrick Donnelly	Downgrade	Buy→Neutral	$375→$300
Feb 16, 2026	Wells Fargo	Brandon Couillard	PT Cut	Equal-Weight	$340→$320
Oct 30, 2025	Citigroup	Patrick Donnelly	PT Raise	Buy	$350→$375
Oct 30, 2025	Wells Fargo	Brandon Couillard	PT Raise	Equal-Weight	$265→$340
Aug 1, 2025	RBC Capital	Conor McNamara	PT Raise	Outperform	$387→$409
Aug 1, 2025	Wells Fargo	Brandon Couillard	PT Raise	Equal-Weight	$245→$265
Jun 9, 2025	Wells Fargo	Brandon Couillard	PT Cut	Equal-Weight	$260→$245
May 2, 2025	UBS	Dan Leonard	PT Cut	Buy	$355→$310
May 2, 2025	Citigroup	Patrick Donnelly	PT Cut	Buy	$400→$350
May 2, 2025	RBC Capital	Conor McNamara	PT Cut	Outperform	$409→$392
Apr 17, 2025	Wells Fargo	Brandon Couillard	PT Cut	Equal-Weight	$320→$270
Apr 8, 2025	RBC Capital	Conor McNamara	PT Cut	Outperform	$430→$409
Mar 28, 2025	Citigroup	Patrick Donnelly	PT Cut	Buy	$450→$400
Feb 14, 2025	RBC Capital	Conor McNamara	PT Cut	Outperform	$477→$447

Analyst Ratings News

PRO
RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $390

RBC Capital analyst Dan Leonard maintains Bio-Rad Laboratories (NYSE:BIO) with a Outperform and raises the price target from $370 to $390.

Benzinga Newsdesk

PRO
Citigroup Maintains Neutral on Bio-Rad Laboratories, Raises Price Target to $330

Citigroup analyst Daniel Grosslight maintains Bio-Rad Laboratories (NYSE:BIO) with a Neutral and raises the price target from $300 to $330.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $370

RBC Capital analyst Dan Leonard maintains Bio-Rad Laboratories (NYSE:BIO) with a Outperform and raises the price target from $320 to $370.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Bio-Rad Laboratories, Raises Price Target to $330

Wells Fargo analyst Evan Stampler maintains Bio-Rad Laboratories (NYSE:BIO) with a Equal-Weight and raises the price target from $310 to $330.

Benzinga Newsdesk

PRO
RBC Capital Reinstates Outperform on Bio-Rad Laboratories, Announces $320 Price Target

RBC Capital analyst Dan Leonard reinstates Bio-Rad Laboratories (NYSE:BIO) with a Outperform and announces $320 price target.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Bio-Rad Laboratories, Lowers Price Target to $290

Wells Fargo analyst Brandon Couillard maintains Bio-Rad Laboratories (NYSE:BIO) with a Equal-Weight and lowers the price target from $320 to $290.

Benzinga Newsdesk

Bio-Rad Laboratories Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Bio-Rad Laboratories Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $390

PRO
Citigroup Maintains Neutral on Bio-Rad Laboratories, Raises Price Target to $330

PRO
RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $370

PRO
Wells Fargo Maintains Equal-Weight on Bio-Rad Laboratories, Raises Price Target to $330

PRO
RBC Capital Reinstates Outperform on Bio-Rad Laboratories, Announces $320 Price Target

PRO
Wells Fargo Maintains Equal-Weight on Bio-Rad Laboratories, Lowers Price Target to $290

People Also Watch

People Also Watch

Bio-Rad Laboratories Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Bio-Rad Laboratories Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRORBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $390

PROCitigroup Maintains Neutral on Bio-Rad Laboratories, Raises Price Target to $330

PRORBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $370

PROWells Fargo Maintains Equal-Weight on Bio-Rad Laboratories, Raises Price Target to $330

PRORBC Capital Reinstates Outperform on Bio-Rad Laboratories, Announces $320 Price Target

PROWells Fargo Maintains Equal-Weight on Bio-Rad Laboratories, Lowers Price Target to $290

People Also Watch

People Also Watch

PRO
RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $390

PRO
Citigroup Maintains Neutral on Bio-Rad Laboratories, Raises Price Target to $330

PRO
RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $370

PRO
Wells Fargo Maintains Equal-Weight on Bio-Rad Laboratories, Raises Price Target to $330

PRO
RBC Capital Reinstates Outperform on Bio-Rad Laboratories, Announces $320 Price Target

PRO
Wells Fargo Maintains Equal-Weight on Bio-Rad Laboratories, Lowers Price Target to $290